Navigation Links
Forest Laboratories Announces Federal Appeals Court Upholds Lexapro(R) Patent Decision

NEW YORK, Sept. 5 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. (NYSE: FRX) and H. Lundbeck A/S of Denmark said today that the U.S. Court of Appeals for the Federal Circuit has affirmed a July 13, 2006 decision by the U.S. District Court for the District of Delaware which determined that the U.S. patent covering escitalopram, the active ingredient in Lexapro(R), is valid and upheld the injunction preventing Ivax/Teva's proposed generic product launch, thereby confirming Forest's and Lundbeck's patent rights for Lexapro(R), which expire in March 2012.

(Logo: )

The patent at issue in the U.S. lawsuit is Lexapro's patent (U.S. Patent No. Re 34,712), which is set to expire in March 2012 and covers substantially pure escitalopram.

About Forest Laboratories and Its Products

Forest Laboratories ( is a US-based pharmaceutical company dedicated to identifying, developing and delivering products that make a positive difference in peoples' lives. Forest Laboratories' growing product line includes Lexapro(R) (escitalopram oxalate), an SSRI indicated for adults for the initial and maintenance treatment of major depressive disorder and generalized anxiety disorder; Namenda(R) (memantine HCl), an N-methyl D- aspartate (NMDA)-receptor antagonist indicated for the treatment of moderate to severe Alzheimer's disease; Benicar(R)* (olmesartan medoxomil), an angiotensin receptor blocker, and Benicar* HCT(R) (olmesartan medoxomil- hydrochlorothiazide), an angiotensin receptor blocker and diuretic combination product, each indicated for the treatment of hypertension; and Campral(R)* (acamprosate calcium), indicated in combination with psychosocial support for the maintenance of abstinence from alcohol in patients with alcohol dependence who are abstinent at treatment initiation.

*Benicar is a registered trademark of Daiichi Sankyo, Inc., and Campral is a registered trademark of Merck Sante s.a.s., subsidiary of Merck KGaA, Darmstadt, Germany.

Except for the historical information contained herein, this release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve a number of risks and uncertainties, including the difficulty of predicting FDA approvals, the acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, the timely development and launch of new products, and the risk factors listed from time to time in the Forest Laboratories' SEC reports, including the Company's Annual Report on Form 10-K for the fiscal year ended March 31, 2007 and quarterly report on form 10-Q for the period ended June 30, 2007.

SOURCE Forest Laboratories, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. DeForest biodiesel plant begins production
2. Biodiesel plant being built in DeForest to make alternative fuel
3. Use of X-rays to advance wood-decay knowledge leads to honor for Forest Products Lab biologist
4. Biodiversity threatened as forests become islands of green, UW professor says
5. BioRobot MDx standardize your automated protocols in clinical laboratories
6. Distance-Learning Remote Laboratories using LabVIEW
7. States are the best laboratories for healthcare reform
8. Scientific Protein Laboratories Acquired by New York firm
9. Speaker announces business members of IT Task Force
10. Doyle announces technology tax credits for Berbee
11. Doyle announces new energy, global warming policies
Post Your Comments:
(Date:11/24/2015)... -- --> --> ... Market by Product & Services (Primer, Probe, Custom Oligos, ... End-User (Research, Pharmaceutical & Biotech, Diagnostic Labs) - Global ... expected to reach USD 1,918.6 Million by 2020 from ... 10.1% during the forecast period. Browse 183 ...
(Date:11/24/2015)...  Tikcro Technologies Ltd. (OTCQB: TIKRF) today announced that its Annual General ... a.m. Israel time, at the law offices of ... 36 th Floor, Tel Aviv, Israel . ... Izhak Tamir to the Board of Directors; , election ... , approval of an amendment to certain terms of options granted to ...
(Date:11/24/2015)... ... November 24, 2015 , ... Creation Technologies ... being named to Deloitte's 2015 Technology Fast 500 list of the fastest growing ... a FDA-cleared, Class II medical device that speeds up orthodontic tooth movement by ...
(Date:11/24/2015)... MUNICH and NEW YORK , ... irst investment by Bristol-Myers Squibb in a ... Bristol-Myers Squibb Company in which the companies ... products in immuno-oncology and other areas of unmet medical need. ... Squibb in LSP 5, the latest LSP fund. This is ...
Breaking Biology Technology:
(Date:11/9/2015)... , Nov. 9, 2015  Synaptics Inc. (NASDAQ: ... today announced broader entry into the automotive market with ... match the pace of consumer electronics human interface innovation. ... are ideal for the automotive industry and will be ... Europe , Japan ...
(Date:10/29/2015)... Daon, a global leader in mobile biometric ... new version of its IdentityX Platform , IdentityX ... have already installed IdentityX v4.0 and are ... FIDO UAF certified server component as an option ... features. These customers include some of the largest and ...
(Date:10/27/2015)... , Oct. 27, 2015 In the present ... of concern for various industry verticals such as banking, ... to the growing demand for secure & simplified access ... ,sectors, such as hacking of bank accounts, misuse of ... equipment such as PC,s, laptops, and smartphones are expected ...
Breaking Biology News(10 mins):